Tag

Peptides

All articles tagged with #peptides

health1 day ago•9 min saved

Sunshine State's peptide boom: promises, perils, and regulatory gaps

Florida is seeing a surge in injections of unapproved, often online-sold peptides promoted by clinics and social media influencers. While some advocates claim benefits for recovery, sleep, fat loss and anti-aging, most peptides lack robust safety data and proven efficacy. Experts warn about quality control issues, impurities, immune reactions, and potential cancer risk, plus a lack of standardized dosing. Regulators are considering tighter access through compounding pharmacies, but costs vary widely—from around $30 for raw powders to $1,500+ per month for clinic programs—and insurance rarely covers them. The trend highlights ongoing tensions between hype, science, and patient safety.

via Sun Sentinel|

#florida #health #influencers

health6 days ago•134 min saved

FDA may expand access to unapproved peptides, but safety remains unsettled

A FDA advisory panel voted to increase access to six unapproved peptides via compounding pharmacies with prescriptions, potentially changing peptide regulation. Experts caution that being more accessible does not mean these peptides are proven safe or effective—many remain untested and unregulated—though compounding could improve purity. The panel's recommendation is not final, and formal rulemaking is required; consumers should weigh potential benefits against significant safety uncertainties.

via Live Science|

#compounding-pharmacies #fda #health

health12 days ago•7 min saved

The Sleep-Peptide Boom: Can Sermorelin Unlock Deeper Sleep?

The article examines sermorelin, a lab-made peptide used off-label to boost deep sleep. While some users report better sleep and faster recovery, experts say evidence is weak, long-term risks are unknown, and unregulated products may carry harmful ingredients; doctors advocate safer, proven sleep strategies like exercise over sermorelin.

via GQ|

#health #off-label #peptides

sciencehealth-policy19 days ago•7 min saved

Regulatory Clash as Online Peptide Craze Outpaces Science

The online hype around MOTS-c and other peptides has spawned unregulated use with little human safety data; researchers press for quality-controlled, prescriber-supervised compounding as a safer alternative to the black market, while FDA staff warn against it due to safety gaps; an FDA panel narrowly backed allowing six peptides to be manufactured via compounding—sparking a policy fight over access, safety, and the future of peptide therapies.

via Los Angeles Times|

#compounding-pharmacies #fda #mots-c

health-policy23 days ago•4 min saved

FDA Panel Backs Six Peptides for Compounding, But Legal Access Hangs on Rulemaking

An FDA Pharmacy Compounding Advisory Committee narrowly recommended six of seven peptides for inclusion on the 503A Bulks List—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—with emideltide rejected. The vote advances a nonbinding advisory step, but none of the substances is FDA-approved and final access hinges on proposed and final rulemaking. Available studies are short and small, leaving safety and efficacy data weak. The panel's reconstitution drew scrutiny over conflicts of interest, and payers should expect continued out-of-pocket use and online sourcing, with emphasis on careful medication reconciliation and safety monitoring until more data are available.

via ajmc.com|

#503a #compounding #fda

health27 days ago•7 min saved

FDA panel backs broader access to six peptides through compounding pharmacies

An FDA advisory committee voted to recommend expanding access to six peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon) by adding them to the 503A Bulks List, potentially enabling licensed pharmacies to prepare prescriptions instead of relying on unregulated online sources. The vote covers six of seven peptides reviewed; the FDA must still issue a final decision. While supporters view it as progress toward safer access, experts caution that safety and efficacy data vary across peptides and emphasize requiring qualified clinicians, licensed pharmacies, quality testing, and patient monitoring—without treating this as blanket approval.

via Fox News|

#compounding-pharmacies #drug-regulation #fda

health29 days ago•7 min saved

FDA Panel Bets Big on Six Peptides Amid Safety Debates

An FDA advisory panel voted to recommend approving six of seven peptides previously banned, including BPC-157, TB-500, KPV, MOTS-c, Emideltide, and Semax (Epitalon was rejected), signaling a potential surge in a U.S. peptide industry but drawing scrutiny over safety data and whether it will curb the gray market; final agency approval remains uncertain and could stretch into 2027.

via GQ|

#fda #gray-market #health

beauty29 days ago•11 min saved

PDRN Skincare: The Salmon-Derived Ingredient Filling Wrinkles

A HuffPost Shopping piece explains polydeoxyribonucleotide (PDRN), a salmon-sperm–derived DNA ingredient touted to boost collagen and hydration to reduce wrinkles. It profiles popular Korean PDRN products—from Iope’s PDRN Caffeine Shot serum to Medicube’s five-peptide formulas and VT Cosmetics’ PDRN 100 Essence—along with Rejuran Turnover ampoule and other novel formulations, while noting plant-based vegan PDRN options and the experts’ caveats about endorsements.

via HuffPost|

#anti-aging #beauty #collagen

health1 month ago•17 min saved

FDA Panel Clears 6 of 7 Banned Peptides for Compounding, Sparking Safety Debate

An FDA Pharmacy Compounding Advisory Committee voted to remove six peptides from the Category 2 ban list (BPC-157, KPV, TB-500, MOTs-C, epitalon, semax) while keeping emideltide restricted, signaling broader access to unapproved peptides via compounding despite limited safety and efficacy data; the non-binding recommendations come amid RFK Jr.’s push to expand peptide use, raising questions about real-world safety and effectiveness.

via Gizmodo|

#compounding #fda #health

biotech1 month ago•1 min saved

Peptides win FDA panel ok, CRISPR tragedy raises ethics questions, insulin supply tightens biotech spotlight

An FDA panel narrowly approved allowing compounding pharmacies to produce certain unregulated peptides—a win for RFK Jr.—while Science reports a six-year-old girl's death in China after an experimental brain-directed CRISPR therapy, prompting ethics and oversight concerns; Sanofi insulin pens are in short supply, underscoring ongoing biotech and pharmaceutical tensions.

via STAT|

#biotech #crispr #ethics

health1 month ago•4 min saved

Kennedy-Linked FDA Panel Clears Path for Peptide Manufacturing Amid Data Gaps

An FDA advisory panel voted to lift manufacturing restrictions on four peptides for human use despite limited safety and efficacy data, a move critics say was influenced by RFK Jr. and his allies; the FDA could still reject or adopt the panel's recommendation.

via Ars Technica|

#advisory-committee #fda #health

health-policy1 month ago•8 min saved

Kennedy pushes peptide access as FDA panel weighs compounding route

An FDA advisory panel appointed by Health Secretary RFK Jr. recommended allowing licensed compounding pharmacies to produce several peptides with prescriptions, signaling a shift away from the FDA’s caution over safety and efficacy. Supporters argue it would curb a thriving unregulated market and expand patient access via providers, while critics warn it could bypass formal FDA review and safety safeguards. The final decision remains with the FDA, though Kennedy has authority to overrule agency conclusions, potentially reshaping the peptide market and care options.

via Politico|

#compounding #fda #health-policy

science1 month ago•6 min saved

AI-Discovered BRP: Tiny Brain Peptide Could Target Appetite More Precisely

Stanford researchers, aided by AI, identify BRP, a 12-amino-acid peptide derived from a prohormone, which reduces food intake and fat in mice and minipigs by acting mainly in the hypothalamus, potentially offering a more targeted obesity treatment with fewer side effects than Ozempic; human testing and receptor mapping are pending.

via ScienceDaily|

#artificial-intelligence #metabolism #neuroscience

health1 month ago•5 min saved

FDA panel nudges peptide rules closer to clinics despite scientific uncertainty

An FDA advisory panel narrowly voted to loosen restrictions on four peptides (BPC-157, KPV, TB-500, MOTS-c), recommending they be added to the list of compounds that compounding pharmacies may produce, even as agency scientists warned about a lack of evidence and unclear chemical identities; the final decision will come from an FDA rule proposal, with votes showing notable dissent and ongoing safety and data concerns.

via NBC News|

#compounding #fda #health

health1 month ago•4 min saved

FDA Panel Signals Move to Loosen Rules on Controversial Peptides

An FDA advisory panel voted to loosen restrictions on controversial peptides such as BPC-157, TB-500, and KPV, potentially allowing specialized pharmacies to produce them and move toward prescription access, despite limited human safety data and ongoing scrutiny; the decision is non-final and faces further debate.

via BBC|

#bpc-157 #fda #health